Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer Inc. (NYSE: PFE) announced that its gene therapy candidate PF-06939926 for Duchenne muscular dystrophy (DMD) has received Fast Track designation from the FDA. This designation aims to accelerate development for serious conditions with unmet needs. Preliminary data from a Phase 1b study indicated that PF-06939926 was well-tolerated and showed sustained dystrophin expression over 12 months. Pfizer aims to advance to a Phase 3 program swiftly, highlighting the urgent need for effective treatment options for DMD, which affects approximately 10,000 to 12,000 individuals in the U.S.
Pfizer Inc. (NYSE: PFE) has received FDA approval for XELJANZ® (tofacitinib) to treat children and adolescents aged 2 and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). The approval includes both a tablet and an oral solution formulation. This marks XELJANZ as the first approved Janus kinase (JAK) inhibitor for pcJIA in the U.S. The approval was based on a Phase 3 study demonstrating significant efficacy, with disease flare rates lower in tofacitinib-treated patients compared to placebo. XELJANZ tablets are available now, while the oral solution is expected by Q1 2021.
Pfizer (NYSE: PFE) and EMD Serono report the publication of Phase III JAVELIN Bladder 100 study results, demonstrating BAVENCIO® (avelumab) as an effective first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma (UC). The study highlighted a significant overall survival (OS) improvement, with 71.3% of BAVENCIO patients alive at one year compared to 58.4% on best supportive care (BSC). FDA approved BAVENCIO in June for this use, based on these results, marking a potential shift in UC treatment protocols.
Find Your MBC Voice, an initiative by Pfizer (NYSE:PFE), is launched with television host Meredith Vieira to empower those living with metastatic breast cancer (mBC). The program offers resources, including a Treatment Discussion Guide, to facilitate informed discussions between patients and doctors about treatment options. An accompanying feature, WMBC Radio, will present insights into managing mBC through interviews with advocates and healthcare professionals. Pfizer emphasizes the importance of empowering patients to advocate for their health.
The FDA has approved BAVENCIO® (avelumab) for maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC) who have not progressed after first-line platinum-containing chemotherapy. This approval follows the Phase III JAVELIN Bladder 100 study, which showed a median overall survival of 21.4 months with BAVENCIO compared to 14.3 months with best supportive care alone, representing a 31% reduction in death risk. This makes avelumab the first immunotherapy to significantly improve survival in this setting, marking a crucial advancement in bladder cancer treatment.